What route of administration is commonly used for leukotriene inhibitors?

Leukotriene inhibitors are primarily administered orally, making this the correct choice. This route is preferred for several reasons. First, oral administration allows for convenient dosing, as these medications are typically available in tablet or liquid form, making them easy for patients to take at home.

Additionally, the oral route ensures that the drug is absorbed through the gastrointestinal tract into the systemic circulation, allowing for a longer duration of action and a steady therapeutic effect on leukotriene pathways, which are involved in inflammatory responses in conditions such as asthma and allergic rhinitis. By inhibiting leukotrienes, these medications help reduce bronchoconstriction, mucus production, and airway edema, which are key factors in respiratory conditions.

Other routes like intravenous, inhalation, and subcutaneous are less common for leukotriene inhibitors. Intravenous administration is typically used for more immediate effects in acute situations, while inhalation is more suited for bronchodilators or corticosteroids that act directly on the lungs. Subcutaneous administration is also not standard for this class of medication, as it is not designed for quick systemic effects and is usually reserved for different types of therapies. Thus, the oral route aligns best with the pharmacological purpose and patient compliance for leukotriene inhibitors.